The most common treatment-related adverse events (TRAE) were lymphopenia (n = 7), leukopenia (n = 5), fatigue (n = 5), neutropenia (n = 4), myalgias (n = 4) and liver function abnormalities (alanine aminotransferase (ALT) elevation n = 5; aspartate aminotransferase (AST) elevation n = 4). This evidence concerns the gene GPT and Decreased total neutrophil count.